1. PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells .
Actividad del Irvalec en la Membrana de las Celulas Tumorales :
Altogether, these effects reflect a severe membrane damage caused by the drug. Interestingly, cell membrane damage was observed only after reaching a threshold concentration of around 3 µM. Similar results were observed with HeLa cervix adenocarcinoma and Hep-G2 hepatocarcinoma cells. Together, these results indicate that PM02734 may exert its potent cytotoxic activity by inducing rapid and severe membrane damage.
******************************************************************
2. Characterization of genetic factors associated with sensitivity to Irvalec, a novel marine-derived compound
Estudio Comparativo entre varios Farmacos para evaluar cual es el Más Potente Inhibidor de ERB-B..... queda Claro que el más Potente es Nuestro Irvalec :
*.- Antiproliferative effects of Irvalec, lapatinib, gefitinib, erlotinib, cetuximab and trastuzumab were evaluated in a panel of colon (HT29, HCT116, Colo205, HCC2998), breast (MCF7, MDA-MB-435, SKBR3, ZR-75-1), ovarian (OVCAR3, IGROV1), lung (Hop62, Hop92), prostate (PC3, DU145), Head&Neck (SCC61, SQ20B, HEP2), and pancreatic (MiaPaCa2, CAPAN1) cancer cell lines using the MTT assay. Expression of Erb-B1, 2, 3 and 4 was evaluated using quantitative RT-PCR.
*.- Conclusions:
Irvalec displays an original cytotoxicity profile, being a more potent inhibitor of cell proliferation than other Erb-B inhibitors in a large panel of human cancer cell lines. Activating mutations of KRAS and EMT were observed in cells resistant to Irvalec. Our data suggest that Erb-B2-4 play a role in sensitivity to Irvalec requiring further investigations.